Available Aripiprazole Long-Acting Injectable Vial Strengths
Aripiprazole long-acting injectable is available in multiple formulations with distinct vial strengths: aripiprazole monohydrate comes in 400 mg (once-monthly) and 960 mg (every 2 months), while aripiprazole lauroxil is available in 441 mg, 662 mg, 882 mg, and 1064 mg strengths.
Aripiprazole Monohydrate Formulations
The aripiprazole monohydrate LAI formulations include:
- 400 mg vial for once-monthly administration 1, 2
- 960 mg vial (2-month ready-to-use formulation) for administration every 2 months 3, 4, 2
The 960 mg bimonthly formulation was specifically designed to cover all recommended oral aripiprazole doses (10-20 mg) and delivers mean steady-state plasma concentrations of 263 ng/mL, well above the therapeutic threshold of 95 ng/mL 3, 4.
Aripiprazole Lauroxil Formulations
Aripiprazole lauroxil, a prodrug of aripiprazole, is available in:
- 441 mg for monthly administration 1
- 662 mg for monthly administration 1
- 882 mg for monthly or every 6-week administration 1
- 1064 mg for administration every 2 months 3, 4
The 882 mg dose has the unique flexibility of being approved for both monthly and every-6-week dosing intervals based on its pharmacokinetic profile 1. The 1064 mg bimonthly formulation delivers mean steady-state concentrations of 140.7 ng/mL 3.
Clinical Considerations
The choice between formulations should prioritize the patient's previous aripiprazole response, desired dosing interval, and need for rapid therapeutic attainment. The aripiprazole lauroxil 1064 mg formulation may require a 1-day initiation regimen, while the aripiprazole monohydrate 960 mg ready-to-use formulation does not 4. Both bimonthly formulations maintain therapeutic plasma concentrations above 95 ng/mL throughout the 2-month dosing interval, though the monohydrate formulation achieves higher mean concentrations 3.